Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AR
Artiva Biotherapeutics, Inc. Common Stock
ARTV
Mkt Cap
$286.0M
Volume
523.40K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AR
ARTV
AR
Artiva Biotherapeutics, Inc. Common Stock
ARTV
News
·
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Mkt Cap
$296.3M
Volume
523.40K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Miralles brings over 20 years of biotech leadership experience and previously served on Artiva's Board. The appointment comes as Artiva prepares for Phase 3 registrational trials of its lead program AlloNK in refractory rheumatoid arthritis, with plans to file a BLA in 2029.
GlobeNewswire Inc. · May 19, 2026
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments include positive Phase III results for Lynk Pharmaceuticals' zemprocitinib, FDA Fast Track designation for Artiva Biotherapeutics' AlloNK, and multiple licensing agreements signaling significant innovation in the RA treatment landscape.
GlobeNewswire Inc. · Apr 28, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics announced that its management will participate in a panel and fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The clinical-stage biotech company is developing cell therapies for autoimmune diseases and cancers, with its lead program AlloNK currently in three ongoing clinical trials for B-cell driven autoimmune diseases.
GlobeNewswire Inc. · Apr 8, 2026
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, bringing over 30 years of global leadership experience in pharmaceuticals, biotechnology, and medical devices. Huston received an inducement grant of 220,000 restricted stock units vesting over four years. The appointment comes as Artiva prepares to receive FDA feedback on its lead program AlloNK and share clinical efficacy data in rheumatoid arthritis in the first half of 2026.
GlobeNewswire Inc. · Feb 24, 2026
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported treating over 100 patients with AlloNK across autoimmune and oncology indications, receiving FDA Fast Track Designation for refractory rheumatoid arthritis treatment. The company expects initial clinical response data in first half of 2026 and has $123 million cash runway into Q2 2027.
GlobeNewswire Inc. · Nov 12, 2025
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight
The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.
GlobeNewswire Inc. · Feb 28, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AR
ARTV
Artiva Biotherapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ARTV
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ARTV yet.
Related Tickers
Earnings